OncoMatch/Clinical Trials/NCT04701476
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Is NCT04701476 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including TATE and pembrolizumab and TAS-102 pill for colorectal cancer; lung cancer.
Treatment: TATE and pembrolizumab · TAS-102 pill · Regorafenib Pill — Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Biomarker criteria
Required: EGFR wild-type
NSCLC without EGFR or AKT mutations
Required: AKT1 wild-type
NSCLC without EGFR or AKT mutations
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy
mCRC progressed on at least two lines of standard chemotherapy
Must have received: chemotherapy
NSCLC progressed on chemotherapy
Must have received: checkpoint inhibitor
NSCLC progressed on ... an immune checkpoint inhibitor
Cannot have received: organ transplantation
Prior organ transplantation
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Irvine Medical Center · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify